REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

T. Yoshino; T. Yamanaka; T. Denda; Y. Tsuji; K. Shinozaki; Y. Komatsu; Y. Kobayashi; J. Furuse; H. Okuda; M. Asayama; K. Akiyoshi; Y. Kagawa; T. Kato; E. Oki; T. Ando; Y. Hagiwara; Y. Ohashi; K. Shitara

doi:10.1093/annonc/mdy150.009

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

T. Yoshino, T. Yamanaka, T. Denda, Y. Tsuji, K. Shinozaki, Y. Komatsu, Y. Kobayashi, J. Furuse, H. Okuda, M. Asayama, K. Akiyoshi, Y. Kagawa, T. Kato, E. Oki, T. Ando, Y. Hagiwara, Y. Ohashi, K. Shitara

消化管外科(2)

研究成果: Contribution to journal › Article › 査読

本文言語	英語
ページ（範囲）	v95
ジャーナル	Annals of oncology : official journal of the European Society for Medical Oncology
巻	29
DOI	https://doi.org/10.1093/annonc/mdy150.009
出版ステータス	出版済み - 6 1 2018

All Science Journal Classification (ASJC) codes

Hematology
Oncology

文献へのアクセス

10.1093/annonc/mdy150.009

引用スタイル

Yoshino, T., Yamanaka, T., Denda, T., Tsuji, Y., Shinozaki, K., Komatsu, Y., Kobayashi, Y., Furuse, J., Okuda, H., Asayama, M., Akiyoshi, K., Kagawa, Y., Kato, T., Oki, E., Ando, T., Hagiwara, Y., Ohashi, Y., & Shitara, K. (2018). REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v95. https://doi.org/10.1093/annonc/mdy150.009

REVERCE : Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. / Yoshino, T.; Yamanaka, T.; Denda, T.; Tsuji, Y.; Shinozaki, K.; Komatsu, Y.; Kobayashi, Y.; Furuse, J.; Okuda, H.; Asayama, M.; Akiyoshi, K.; Kagawa, Y.; Kato, T.; Oki, E.; Ando, T.; Hagiwara, Y.; Ohashi, Y.; Shitara, K.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v95.

研究成果: Contribution to journal › Article › 査読

Yoshino, T, Yamanaka, T, Denda, T, Tsuji, Y, Shinozaki, K, Komatsu, Y, Kobayashi, Y, Furuse, J, Okuda, H, Asayama, M, Akiyoshi, K, Kagawa, Y, Kato, T, Oki, E, Ando, T, Hagiwara, Y, Ohashi, Y & Shitara, K 2018, 'REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v95. https://doi.org/10.1093/annonc/mdy150.009

Yoshino T, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y et al. REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 6 1;29:v95. https://doi.org/10.1093/annonc/mdy150.009

Yoshino, T. ; Yamanaka, T. ; Denda, T. ; Tsuji, Y. ; Shinozaki, K. ; Komatsu, Y. ; Kobayashi, Y. ; Furuse, J. ; Okuda, H. ; Asayama, M. ; Akiyoshi, K. ; Kagawa, Y. ; Kato, T. ; Oki, E. ; Ando, T. ; Hagiwara, Y. ; Ohashi, Y. ; Shitara, K. / REVERCE : Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. v95.

@article{a81853b3711e4d0e909b25c63aa3b5c1,

title = "REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis",

author = "T. Yoshino and T. Yamanaka and T. Denda and Y. Tsuji and K. Shinozaki and Y. Komatsu and Y. Kobayashi and J. Furuse and H. Okuda and M. Asayama and K. Akiyoshi and Y. Kagawa and T. Kato and E. Oki and T. Ando and Y. Hagiwara and Y. Ohashi and K. Shitara",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy150.009",

language = "English",

volume = "29",

pages = "v95",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - REVERCE

T2 - Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

AU - Yoshino, T.

AU - Yamanaka, T.

AU - Denda, T.

AU - Tsuji, Y.

AU - Shinozaki, K.

AU - Komatsu, Y.

AU - Kobayashi, Y.

AU - Furuse, J.

AU - Okuda, H.

AU - Asayama, M.

AU - Akiyoshi, K.

AU - Kagawa, Y.

AU - Kato, T.

AU - Oki, E.

AU - Ando, T.

AU - Hagiwara, Y.

AU - Ohashi, Y.

AU - Shitara, K.

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85081599595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081599595&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy150.009

DO - 10.1093/annonc/mdy150.009

M3 - Article

C2 - 32177324

VL - 29

SP - v95

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -